Skip to main content
. 2023 Jan 22;14(3):367–378. doi: 10.7150/jca.81027

Figure 1.

Figure 1

Erianin significantly decreased the activity of HuRCSCs in vitro. (A) The molecular structure of Erianin. (B) MTT assay results showing that Erianin significantly inhibited the proliferation of HuRCSCs in vitro. **p < 0.01 vs. DMSO; *p < 0.05 vs. DMSO; t test; n = 4. (C) Flow cytometry analysis showing that Erianin induced HuRCSC apoptosis in vitro. **p < 0.01 vs. DMSO; t test; n = 4. (D) Transwell chamber results showing that Erianin significantly inhibited the migration of HuRCSCs in the external matrix. **p < 0.01 vs. DMSO; t test; n = 4. (E) Erianin significantly inhibited the angiogenesis of HUVECs in the external matrix. **p < 0.01 vs. DMSO; t test; n = 4. (F) Biochemical assay showing that Erianin significantly downregulated pyruvate and T-GSH concentrations and upregulated lactic acid, LPO, and Fe2+ concentrations in HuRCSCs. **p < 0.01 vs. DMSO; *p < 0.05 vs. DMSO; t test; n = 4. (G) The MTT results showing that the cell inhibition rate of Erianin + Ferr-1 treatment group was significantly decreased. (H) Flow cytometry analysis results indicated that the precentage of BrdU+ HuRCSCs of Erianin treated group was significantly decreased. (I) Flow cytometry analysis results indicated that the precentage of BrdU+ HuRCSCs of Erianin treated group was significantly elevated.